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Abstract
Objectives—A pediatric study has established a maximum tolerated dose (MTD) for
temsirolimus (Tem) of more than 150 mg/m2 IV/week. A phase I trial was conducted to establish
the MTD for Tem in combination with valproic acid (VPA) in children and adolescents with
refractory solid tumors. Secondary aims included expression of mTOR markers on archival tumor
tissue; Tem pharmacokinetics (PK); assessment of histone acetylation (HA); and tumor response.
Methods—Patients were treated with VPA (5mg/kg PO TID) with a target serum level of 75–
100 mcg/mL. Tem was started at an initial dose of 60 mg/m2/week. PK and HA measurements
were performed weeks 1 and 5.
Results—Two of the first 3 subjects experienced dose-limiting toxicity (DLT) (grade 3
mucositis). Tem at 35 mg/m2/week was found to be tolerable. Peak Tem concentrations were
higher in all subjects compared to those in previously published reports of single agent Tem.
Increases in HA correlated with VPA levels. All tumor samples expressed mTORC1 and
mTORC2. An objective response was seen in one patient (melanoma); transient stable disease was
*Corresponding author: 919-966-0590 (tel), 919-966-7629 (fax), jblat@med.unc.edu c/o Division of Pediatric Hematology Oncology,
POB 1185A, 170 Manning Dr., Chapel Hill, NC 27599-7236.
The authors have no conflict of interest.
NIH Public Access
Author Manuscript
Anticancer Drugs. Author manuscript; available in PMC 2014 April 30.
Published in final edited form as:






















seen in 4 other patients (spinal cord ependymoma, alveolar soft part sarcoma; medullary thyroid
carcinoma; hepatocellular carcinoma).
Conclusions—The MTD of Tem when administered with VPA is considerably lower than when
used as a single agent, with mucositis the major DLT. The combination merits further study and
may have activity in melanoma. Attention to drug-drug interactions will be important in future
multi-agent trials including Tem.
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INTRODUCTION
Temsirolimus (Tem) is a selective inhibitor of the mammalian target of rapamycin (mTOR)
which has demonstrated tolerability and efficacy against a wide range of adult cancers [1–6].
In adults, mucositis, rash, and asthenia have been the most common dose limiting toxicities
(DLT) at doses up to 250 mg/m2 [7,8]. However, doses of 15 mg/m2 have been found to
have biologic activity [8] and 25 mg/week is the dose recommended for the single agent
treatment of advanced clear cell renal cell carcinoma, the US Food and Drug Administration
approved indication for Tem [9].
Several mTOR inhibitors have demonstrated significant antitumor activity in both in vitro
and in vivo pediatric solid tumor models, including rhabdomyosarcoma, gliomas, and
neuroblastoma [10–12]. A recent phase I–II study of Tem as a single agent in children found
the drug to be tolerable when given intravenously in doses as high as 150 mg/m2/wk, with
pharmacokinetics similar to those seen in adults [13].
Valproic Acid (VPA) is a histone deacetylase (HDAC) inhibitor that also has shown in vitro
and in vivo anti-tumor activity against a range of cancers in children [14–16]. This is a drug
which has a long history in pediatrics as an anticonvulsant at target serum levels of 50–100
mcg/mL. Both mTOR inhibitors and VPA are inducers of autophagy [17, 18]. Our rationale
for combining Tem and VPA was based on the apparently minimal and largely non-
overlapping toxicities of each of these drugs as single agents, the long track record of VPA
in children, past demonstration of anticancer activity in vitro and in vivo of these drugs as
single agents, and our results of additive effects of these drugs against neuroblastoma in
vitro (D. Coulter, personal communication). A recent report using a similar combination in
vitro in prostate cancer also suggests that it may have some additive effects [19]. The current




Eligibility criteria included male or female patients 2 to 18 years of age with radiographic
evidence of persistent or progressive histologically verified solid tumor after standard
therapy, normal renal, liver, and hematopoietic function using standard criteria (transfusion
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support was permitted for patients with marrow involvement), and an age-appropriate
performance status of at least 50%. Patients must have been off prior cancer-specific
treatment for at least two weeks and must have recovered from prior toxicities. Current use
of anticonvulsants including VPA, or use of CYP3A4 inducers or inhibitors and drugs that
are CYP2D6 substrates were exclusions. Although the intent was to evaluate response based
on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [20], this requirement
was waived for one patient with measurable disease but with lesions smaller than 10 mm.
The study was opened at the University of North Carolina at Chapel Hill in 2009, and at
Levine Children’s Hospital in 2010. Patients or their legal guardians provided written
informed consent approved by the respective institutional review board before study
participation.
Pretreatment evaluations included a medical history, physical examination, performance
status assessment, a complete blood count (CBC) with differential, serum electrolytes, renal
and liver function tests, fasting cholesterol and triglyceride levels, tumor measurements, and
serum or urine pregnancy tests for female participants of childbearing age. Peripheral blood
was collected for mononuclear cell isolation (below). Archival tumor tissue was obtained for
correlative studies (below). Participation was not dependent on mTOR expression.
Study Design
This was an open label single arm dose escalation study of Tem in combination with VPA.
Tem was provided by Pfizer (formerly Wyeth) Pharmaceuticals (Philadelphia, PA). VPA
was commercially available and begun at a dose of 15 mg/kg/day divided TID orally 3–7
days before starting Tem with the intent to achieve trough plasma levels of 75–100 mcg/mL.
Patients were asked to keep daily diaries of VPA use. Tem was administered intravenously
over 30–60 minutes weekly following premedication with diphenhydramine (0.5 – 1 mg/kg
to a maximum dose of 50 mg). After the first patient developed a moderate infusional
reaction, Tem subsequently was infused over 60 minutes without problems. The starting
Tem dose was 60 mg/m2 based on ideal body weight, with the next dose level (dose level -1)
of 35 mg/m2. Achievement of target VPA levels was not required prior to the initiation of
Tem, and VPA doses were titrated over time based on levels and toxicity (below).
A minimum of 3 patients assessable for toxicity was planned at each dose level. Patients
were considered to have tolerated a given dose level if they had received at least 6 weeks of
combination therapy without DLT (defined below). The MTD was to have been defined as
the dose level immediately below that at which two of 6 patients experienced DLTs during
the first 6 weeks of treatment, and the intent was to treat 6 evaluable patients at the MTD.
There was no intra-patient dose escalation. Subjects who experienced a DLT could elect
additional treatment on study at the next lower dose of Tem, or could continue combination
treatment off study at every other week intervals and/or at lower Tem doses at the discretion
of the family and treating clinician. Subjects without DLTs could continue therapy for up to
a year or until disease progression.
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Toxicity was graded according to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.1. Grade 4 thrombocytopenia or neutropenia of more
than 7 days in duration was classified as a hematologic DLT for subjects without marrow
involvement by tumor. Nonhematologic DLTs included all grade 3 or 4 Tem-related
toxicities resulting in delay in treatment for more than two weeks.
Evaluation of response
Tumor measurements were performed before every fourth month of treatment, in the event
of DLT, or if the family elected to come off study after the first 6 weeks. Tumor response
was evaluated using RECIST 1.1 [20]. Patients must have been on study for at least 6 weeks
to be evaluable for efficacy.
Pharmacokinetic Studies
PK studies to measure Tem levels were performed during weeks 1 and 5. Whole-blood
samples (2 mL) were collected in EDTA-treated tubes before Tem administration and at 0.5,
1, 2, 5 and 24 hours after administration. Samples were mixed, transferred into separate
polypropylene tubes, and stored at − 20 °C within 60 minutes of the venipuncture. In all but
subject #6, PK samples were obtained from a site different from that into which Tem had
been administered. Tem concentrations were determined by Liquid Chromatography/Triple
Quadrupole Mass Spectrometry (HPLC/MS-MS) using a previously validated method [21].
The HPLC-MS/MS system consisted of two Shimadzu Scientific (Columbia, MD) solvent
delivery pumps, a Valco (Houston, TX) switching valve, a thermostated (6 °C) LEAP HTC
autosampler (Carrboro, NC), and an Applied Biosystems (Foster City, CA) API3000 triple
quadrupole mass spectrometer. Quality controls, also in whole blood, were prepared in
triplicate. The lower limit of quantitation (LLQ) was 60 ng/mL with all standards and all
controls achieving at least 85% accuracy and precision. A non-compartmental model was fit
to the concentration-time data using Phoenix WinNonlin software, version 6.2 (Pharsight,
Inc., Cary, NC). Individual subject pharmacokinetic profiles and the parameters of area-
under-the-concentration time curve (AUC) 0 to 24 hours post dose, Tmax, Cmax, clearance,
volume of distribution (Vd) and half-life were reported using descriptive statistics.
Immunohistochemistry
Slides from diagnostic paraffin-embedded tissue obtained prior to any chemoradiotherapy
were stained with primary rabbit antibodies to Raptor (mTORC1), Rictor (mTORC2), and
LC3 (Bethyl Laboratories, Montgomery, TX). Antibodies were used at a final dilution of
1:300 in PBS containing 2% horse serum and applied overnight at 4° C. Antibody-antigen
complexes were visualized using a DAKO EnVision System HRP (DAB) kit (DAKO,
Carpinteria, CA) according to the manufacturer’s protocol. Two slides from each sample
were reviewed unblinded (BMMS, JB, SS) and subjectively scored as negative or positive
(weak, intermediate, strong) compared to negative and positive control slides (human lung
squamous cell carcinoma without and with primary antibody).
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Heparinized blood was obtained on 3 subjects prior to initiation of VPA, after 3–7 days on
VPA but before initiation of Tem, and just before the 2nd or 5th Tem dose. Samples were
obtained just prior to the morning dose of VPA. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll gradient centrifugation and stored at −80 C. Cell extracts,
normalized for PBMC number, were separated by SDS-PAGE, transferred to nitrocellulose
and blotted with rabbit anti-tetra-acetyl H4 (Active Motif, 1:2000) and rabbit anti-pan-H4
(Millipore, 1:1000). Western blots were scanned and quantified (Licor Odyssey v. 3.0).
RESULTS
Seven patients were enrolled on study over two years. One patient died within two weeks of
starting treatment due to tumor progression and was considered to be not evaluable.
Characteristics of the 6 evaluable patients are shown in Table 1.
Toxicity
Table 2 summarizes the toxicities observed in patients enrolled on this trial. Grade 3
mucositis was experienced by two of 3 subjects at dose level 1 (60 mg/m2) and was
considered to be dose limiting because it did not improve to grade 1 or 2 within 14 days.
Both of these patients had received radiation therapy to the head and neck, though in each
case the interval between radiation and Tem was more than a year. Subsequent patients
received a decreased Tem dose of 35 mg/m2. Even at this lower dose, all subjects
experienced mucositis limited to grade 1 or 2, with the exception of one subject with grade 3
which did not meet DLT criteria (i.e., the subject recovered within 14 days of treatment and
did not require dose or schedule modification of Tem). Other non-DLTs attributed to Tem
included acne (n=1), a grade 3 allergic infusional reaction consisting of fever, chills and
mild hypotension when Tem was given over 30 minutes (n=1), and chest pain (n=1).
Toxicity seemed to correlate with VPA levels >75 mcg/mL.
The first 3 patients also experienced dose-limiting fatigue which was first noted prior to
initiation of Tem. Because fatigue is a known side effect of VPA, and was identified as a
dose limiting toxicity in a Phase I study of VPA in pediatric patients with solid tumors [16],
the dose of VPA was reduced in an effort to preserve Tem dosing. Thus, serum levels below
the targeted 75 – 100 mcg/mL were allowed, and grade 3 fatigue rather than serum level was
used as the dosing end point. One patient developed grade 2 thrombocytopenia at a VPA
level of 56 mcg/mL which resolved after holding VPA for 3 days. Tem was not held and
VPA was resumed without a recurrent drop in platelets. One subject (#5) developed grade 3
poorly characterized bilateral plantar pain thought to be due to VPA (which is reported to be
a cause of paresthesias), for which both VPA and Tem were suspended for 3 weeks. Because
this toxicity was noted at the beginning of the 4th month of treatment and because it was not
thought to be attributable to Tem, it was not considered to be a DLT. VPA level was 87
mcg/mL at the time of maximum symptoms. The subject was restarted on a reduced dose of
VPA once symptoms had nearly resolved. VPA level after 24 hours at the reduced dose was
52 mcg/mL and Tem was restarted. The patient experienced no recurrence of DLT over her
last 4 weeks of treatment. Patient #6 experienced transient grade 2 chest pain within 24
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hours of courses 4 and 5 of Tem. Dosing of VPA, with confirmation by review of daily
diaries, did not correlate reliably with serum levels in any of the patients. Whether diaries
were true reflections of compliance is not clear.
Because of slow accrual, the study was discontinued after only 3 patients had received 35
mg/m2. Although it is likely that this is the MTD of Tem when given in combination with
VPA, the limited number of subjects treated at this dose raises the possibility that toxicity
might have been observed eventually.
Immunohistochemistry
Expression of both mTORC1 and mTORC2 was intermediate or strong in pretreatment
tumor samples in all patients. None of the pretreatment samples expressed LC3.
Tumor Response
As summarized in Table 3, an objective response (OR) not meeting criteria for a partial
response was seen in one child (#3) with progressive metastatic melanoma. After dose
limiting mucositis following 3 weeks at the 60 mg/m2 dose level, Tem was continued at 35
mg/m2. At his family’s discretion, he came off study following 2 months and received
treatment every 2 weeks. He had a 15% reduction in tumor size by RECIST criteria after 4
months on treatment. However, at his family’s discretion treatment was extended to every
3–4 weeks with minimal increase in tumor size two months later and he came off treatment.
He had clear progressive disease 12 months from the start of Tem/VPA. Two other patients
treated at 60 mg/m2 (alveolar soft part sarcoma [n=1] and spinal cord ependymoma [n=1]),
and two patients treated at 35 mg/m2 (MEN2b and metastatic medullary carcinoma of the
thyroid, and one patient with metastatic hepatocellular carcinoma) had stable disease for 19,
9, 2, and 8 months, respectively. The last patient came off study at 8 months for quality of
life considerations.
Pharmacokinetics
PK parameters were available from cycle 1 in five patients and from cycle 5 in three patients
(Table 4). The median Cmax, AUC, T1/2, CL, and Vd increased with dose during the first
cycle. Only the CL and Vd increased with dose in cycle 5; however, only one patient was
evaluable at the 60 mg/m2 dose level at cycle 5. Patient #2 had a Cmax of 1,210 ng/mL at the
60 mg/m2 dose level and did not receive cycle 5 PK as a result of stopping treatment
secondary to a DLT. Of the two patients who received 60 mg/m2 in cycle 1, the median
Cmax was 1,215 ng/mL, while the three patients who received 35 mg/m2 in cycle 1 had a
median Cmax of 790 mg/m2. The median Cmax reported previously for patients on Tem 25
mg/m2 and 75 mg/m2 without VPA was 448 ng/mL and 442 ng/mL, respectively (13). The
Cmax for our patients who had received 35 mg/m2 in cycle 1 ranged from 649–1,260
ng/mL, averaging twice the Cmax seen at even the 75 mg/m2 dose level in patients without
VPA.
HA measurements
As a marker of HDAC activity, we examined histone H4 acetylation in peripheral blood
mononuclear cells isolated from three subjects for whom there were adequate samples that
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represented pre-treatment as well as after initiation of VPA and after both VPA and Tem.
For two of these subjects, we observed a significant increase in histone acetylation after
treatment with both VPA and Tem but not VPA only (Fig 1AB). The one subject for whom
histone acetylation was not increased had a low VPA level. As VPA doses were adjusted
during the initiation of Tem, data from subject 6 suggest that VPA dose determines histone
acetylation, and that plasma levels of >70 mcg/dL are required to inhibit HDAC activity in
PBMC (Fig 1C).
DISCUSSION
In this phase I study in children and adolescents with refractory pediatric solid tumors, we
demonstrated that a dose of Tem of 35 mg/m2 appeared to be well tolerated when the drug
was combined with VPA. The premature closure of the study due to slow accrual leaves
open the possibility that further dose modification might be needed. Nonetheless, the MTD
of Tem when given with VPA clearly is significantly lower than the MTD reported in
multiple adult trials [1, 8, 9] and in a recent phase I pediatric study of Tem alone (150
mg/m2) [13]. However, it is well above the 10 mg/m2 dose identified by those researchers as
inducing a complete response (CR) in a child with multiply relapsed neuroblastoma.
Previous researchers have shown that doses of Tem as low as 25 mg inhibit mTOR activity
and no relationship has been identified between the dose of Tem and the degree of mTOR
inhibition [1]. The frequent occurrence of dose limiting mucositis in our study contrasts
strikingly with the previously published phase I trial of Tem as a single agent [13], and
suggests that VPA might increase the mucosal toxicity of Tem. Of note, several patients
who continued for many months on study or off study at lower doses and every other week
for prolonged periods after the initial 6 weeks experienced additional side effects, justifying
prolonged monitoring of patients on Tem.
Most of our patients experienced some amount of fatigue. We attributed this effect to VPA
since this often was noted prior to the initiation of Tem and is a known effect of VPA [16,
22], we attributed the fatigue to VPA. Interference with activities of daily living during the
first few weeks of combination therapy required VPA dose reduction. Serum levels often
fell well below the targeted levels of 75–100 mcg/mL, and somnolence became our dosing
endpoint rather than serum levels. However, this seems to have resulted in reduced VPA
levels that were not associated with HDAC activity.
Our PK results offer one explanation for the lower MTD for Tem when combined with VPA
as compared with its MTD as a single agent. Tem Cmax and AUC in children taking VPA
was much higher than previously reported in children taking Tem without VPA [13]. Peak
Tem levels in the 60 mg/m2 dose level at both cycles ranged from 757–1,220 ng/mL
compared to 369–630 ng/mL seen in children who had received 75 mg/m2 Tem in the
previous study. The higher Cmax and greater exposure of Tem at the 60 mg/m2 dose level
may have resulted in DLTs. Interestingly, one patient who discontinued treatment due to
dose-limiting mucositis had a Cmax of 1,210 ng/mL during cycle 1, nearly three times the
Cmax reported in patients taking Tem 75 mg/m2 without VPA. VPA is known to be a broad-
spectrum metabolic inhibitor, primarily inhibiting CYP2C9, but having some competitive
inhibitory effects on CYP3A4 [23]; Tem is primarily metabolized in the liver by CYP3A4
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[21]. These data suggest a possible interaction between Tem and VPA resulting in increased
concentrations of Tem.
In a phase I study of VPA alone [16], increased acetylated H4 was observed in half of the
subjects associated with levels of 55–100 mcg/mL, although others have suggested that
acetylation is not significantly inhibited until levels greater than 100 mcg/mL are achieved
[24]. VPA levels in our subjects were quite variable and in all were below 100 mcg/mL.
Nonetheless, with limited subjects there appeared to be an association between VPA level
and histone acetylation suggesting that Tem might potentiate the affect of VPA on histone
acetylation. Additional patients will need to be studied to clarify this interaction. If
confirmed, a drug-drug interaction may explain the grade 1 or 2 fatigue which was seen
even despite dose reductions and at relatively low plasma levels of VPA.
In the present study, we attempted to preserve Tem by reducing VPA doses. However, this
strategy seems to have diminished HDAC activity which could have compromised the
biological synergy predicted in vitro for combined VPA and Tem treatment. Our MTD of
35mg/m2/wk was met when VPA doses were dropped, using fatigue rather than serum
levels as the eventual endpoint. Reduced Tem MTD has also been associated with
combination treatment with metformin [25]. Together, these studies suggest that Tem, when
given in combination with other agents, may exhibit a unique toxicity profile justifying
study-based evaluation.
Because this was designed as a phase I and not a phase II trial, and because of the
heterogeneous diagnoses of participating subjects, response data were inconclusive.
However, an objective response--while not meeting RECIST criteria for partial response--
was observed in one subject with disseminated melanoma. To what extent response was due
to the combination rather than single agent activity is not clear from this single arm trial.
Lesser responses were observed in children with other diagnoses for which there have been
few therapeutic options. Response was not predicted in this small series by mTORC1 and
mTORC2 staining, which were convincingly expressed in all pretreatment tumor samples.
The combination of Tem and VPA merits further study and may have activity in melanoma.
Attention to drug-drug interactions will be important in future multi-agent trials including
Tem. Additional attention should be paid to managing the side effects that might be specific
to combination agent therapy in order to maintain the intended biologic effects without
significantly compromising quality of life. Phase II trials for diseases such as melanoma for
which there are limited single agent data may need to include two arms to compare the
efficacy of combination therapy with single agent treatment. Because of concerns about
compliance, we remain enthusiastic about intravenous administration of mTOR inhibitors
for future studies.
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Figure 1. Increased histone acetylation was associated with Tem and VPA treatment
A. Extracts of purified peripheral blood mononuclear cells were immunoblotted for tetra-acetyl H4 and total H4. A
representative blot is shown. B and C. Histone acetylation increased after both Tem and VPA treatment in two of three
assayable subject. Signal from H4Ac relative to panH4 +/− SEM is shown. Relative acetylation corresponded with VPA levels
(shown above bars), and levels of > 70 mcg/dL appear to be required to inhibit HDAC activity in PBMC.
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Table 1
Characteristics of evaluable study patients*
Patient Age (Years),
Race, Gender
Diagnosis Prior Treatments Dose level
of Tem,
mg/m2
1 16AAF Alveolar Soft Part Sarcoma ARO197; cyclophosphamide/celebrex; AEWS0031 60
2 13AsWM Spinal cord ependymoma grade II S; RT; cyclophosphamide/celebrex/etoposide 60
3 11WM Melanoma S; carboplatin/taxol 60




5 18WF Medullary carcinoma thyroid S 35
6 17WF Hepatocellular Carcinoma Sorafenib, Doxorubicin 35
*
Abbreviations: RT=radiation therapy; S=surgery; AA=African American; F=female; M=male; As=Asian; M=male; W=white
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Table 3
Response of Study Patients
Patient Diagnosis Dose Tem mg/m2 Response Duration of Treatment (on study)/Response (months)
1 Alveolar Soft Part Sarcoma 60 SD 19 (4.5)/19
2 Spinal cord ependymoma 60 SD 13 (1)/3
3 Melanoma 60 OR 6(2)/12
4 Undifferentiated Sarcoma, NOS 35 PD 2.5 (2.5)/na
5 Medullary Carcinoma Thyroid 35 SD 6 (4)/2
6 Hepatocellular Carcinoma 35 SD 7 (7)/7
Abbreviations: NOS: not otherwise specified; OR: objective response; PR: partial response; SD: stable disease; PD: progressive disease; n/a not
applicable
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Table 4
Summary of Temsirolimus Pharmacokinetic Parameters
Temsirolimus Dose level
Cycle 1 35 mg/m2 60 mg/m2
Median Range Median Range
N = 3 N = 2
Cmax, ng/mL 790 649–1,260 1,215 1,210–1,220
Tmax, hr 0.66 0.5–1.0 1.0 1.0–1.0
T1/2, hr 11.7 8.7–18.1 15.6 8.8–22.3
AUClast, hr* ng/mL 7,554 6,983–9,816 8,330 7,892–8,768
CL, mL/hr 4.5 4.1–6.4 7.1 4.3–9.9
Vd, mL 107 56.5–107 132 126–138
Cycle 5 N = 2 N = 1
Cmax, ng/mL 1,094 968–1220 757 N/A
Tmax, hr 0.5 0.5–0.5 0.5 N/A
T1/2, hr 12.9 7.9–17.9 8.4 N/A
AUClast, hr* ng/mL 9,089 7,638–10,539 6,200 N/A
CL, mL/hr 4.4 2.9–6.0 9.3 N/A
Vd, mL 71.0 67.8–74.1 112 N/A
Abbreviations: AUC, area under the concentration-time curve; CL, clearance; Cmax, maximum concentration; Tmax, time to Cmax; T1/2, half-
life; Vd, steady-state volume of distribution
*
Patient #2 did not receive cycle 5 secondary to toxicity
**
Patient #3 was excluded from PK analysis secondary to an unexpected rise in temsirolimus concentration at the 24 hour PK sample resulting in
inaccurate PK parameters
***
Patient #6, cycle 5 was excluded from PK analysis secondary to lack of 24 hour PK sample
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